Anass JAWHARI – CSO of CALIXAR – will be giving a presentation on CALIXAR expertise in the stabilization of native membrane protein targets for Drug Discovery on October 7th, 2019.
CALIXAR has developed an innovative detergent/surfactant-based approach for therapeutic membrane protein stabilization. GPCRs, ion channels, transporters can be stabilized without any single mutation, truncation, or fusion.
In this presentation, we will illustrate that using the most recent case studies on targets of high medical relevance (such as native adenosine receptor, potassium chloride co-transporter, Multi-drug resistance protein 4, and CD20) for which functional and structural integrities were preserved.
A side-by-side study will be shown using classical detergents, Calixarenes detergents, and SMA polymers to solubilize and stabilize MRP4. Biochemical and biophysical characterization of purified native CD20 alone and in complex with therapeutic antibodies (rituximab and obinutuzumab) will also be discussed. This innovative and integrative approach represents a serious alternative to classical protein engineering approaches to enable drug discovery (SBDD, FBDD, Antibody Discovery & Vaccine).